

# Improving the lifestyle and heart health of siblings and offspring of patients who had a heart attack before the age of 55 in men or the age of 65 in women

<b>Submission date</b> 18/06/2020	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 06/08/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 05/09/2025	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Smoking, poor diet, and lack of exercise are associated with obesity, poor blood pressure, glucose and cholesterol control, all being risk factors that lead to coronary heart disease. However, if lifestyle factors such as cigarette smoking, physical inactivity and unhealthy diet are modified, there might be a substantial decrease in coronary heart disease risk. If people are screened and identified, this will provide an opportunity for prevention to take place before the establishment of the disease, hence preventing or delaying the disease. The aim of this study is to evaluate the feasibility and acceptability of a preventive cardiology programme designed to promote risk reduction in a sample of relatives of patients with premature coronary heart disease.

### Who can participate?

People aged 30 and older who have a brother or a sister or parents who had a heart attack before the age of 55 in men or the age of 65 in women

### What does the study involve?

The study will consist of four separate visits of around 1 hour each (baseline assessment, CRISO lifestyle intervention programme/verbal lifestyle advice only, 6-month follow-up, 12-month follow-up). Participants are randomly allocated to the intervention group or the control group. Participants in the intervention group will have an initial face-to-face session (evaluation of modifiable risk factors, two-way risk factor communication, education and individualised counselling to set up a cardioprotective plan) followed by weekly telephone-based cardioprotective reinforcement sessions for up to 12 weeks. Participants in the control group will have a limited intervention consisting of one face-to-face session of lifestyle advice only.

What are the possible benefits and risks of participating?

Benefits could be weight, blood pressure and blood glucose improvement. The assessment techniques are safe and potential risks are very minimal. Some bruising is possible after blood sampling.

Where is the study run from?

Mater Dei Hospital (Malta)

When is the study starting and how long is it expected to run for?

June 2016 to September 2022

Who is funding the study?

University of Malta (Malta)

Who is the main contact?

Justin Lee Mifsud

justin-lee.mifsud@um.edu.mt

## Contact information

### Type(s)

Scientific

### Contact name

Mr Justin Lee Mifsud

### ORCID ID

<https://orcid.org/0000-0001-5380-9418>

### Contact details

University of Malta

Office 38

Faculty of Health Sciences

Msida

Malta

MSD 2080

+356 (0)79433879

justin-lee.mifsud@um.edu.mt

### Type(s)

Scientific

### Contact name

Prof Joseph Galea

### Contact details

University of Malta

Faculty of Medicine and Surgery

Msida

Malta

MSD 2080

+356 (0)99823852  
joseph.f.galea@um.edu.mt

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

HEC03 CT01/20

## Study information

### Scientific Title

Feasibility and acceptability of a coronary risk reduction intervention for siblings and offspring of patients with premature coronary heart disease

### Acronym

CRISO

### Study objectives

The aim of this study is to evaluate the feasibility and acceptability of a drafted preventive cardiology programme, designed to promote risk reduction in a sample of asymptomatic first-degree relatives of patients with premature coronary heart disease (CHD).

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

1. Approved 04/08/2020, University of Malta Research Ethics Committee (University of Malta, Msida MSD 2080; +356 (0)23402340; research-ethics.ms@um.edu.mt), ref: UNIQUE FORM ID: 3756\_191119
2. Approved 04/08/2020, Health Ethics Committee Malta (Health Ethics Committee, Directorate for Health Information & Research 95, Gwardamangia Hill, Pieta' - Malta PTA 1313 address; +356 (0)25599000; hec@gov.mt), ref: HEC03 CT01/20

### Study design

Randomised single-centre two-armed group randomized controlled trials with embedded interviews

### Primary study design

Interventional

### Study type(s)

Prevention

### Health condition(s) or problem(s) studied

First degree relatives of patients with premature coronary heart disease

## **Interventions**

Block randomization will be applied to balance out sample size between intervention group and control group. Block randomization of four rows of relatives, using an opaque sealed envelope technique, will be implemented for this study.

**Intervention:** Participants will have an initial face-to-face session (evaluation of modifiable risk factors, two-way risk factor communication, education and individualised counselling to set up a cardio-protective plan) followed by weekly telephone-based cardio-protective reinforcement sessions for up to 12 weeks.

**Control:** Participants will have limited intervention, consisting of one face to face session of lifestyle advice only.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Feasibility measured using records of the number of:

1. Relatives recruited via patients - measured at recruitment stage
2. Relatives recruited via social media - measured at recruitment stage
3. Relatives recruited via poster method (local councils, pharmacies, social groups) - measured at recruitment stage
4. Relatives who expressed interest in the study - measured at recruitment stage
5. Relatives who are potentially eligible, with reasons for ineligibility - measured at recruitment stage
6. Relatives who agreed to participate in the trial - measured at recruitment stage
7. Relatives lost to follow-up (retention and drop-out rate) - measured at 12 months
8. Sessions delivered successfully - measured at 12 months

Furthermore, the feasibility of the intervention will include the time taken to:

1. Complete cardiovascular risk assessment - measured at baseline, 6 months and 12 months.
2. Deliver the intervention (in-person session and telephone sessions) - time recorded for the individualized intervention session (in-person session and telephone sessions)

Acceptability will be evaluated by determining how well the intervention is received by first degree relatives and the extent to which this intervention could meet the needs of first-degree relatives. This requires data of the participants' most valued intervention components in terms of being supportive and the participants' views of the quality of interactions during intervention sessions, along with how well the intervention targets can be incorporated into participants' personal lifestyles, taking into consideration any difficulties that were experienced while attempting to comply with the programme goals. To collect this data, post-intervention questionnaires and interviews will be used. This data will determine which part of the intervention the participants found most supportive and which parts may require further refinement. Evaluated at 12 months.

## **Key secondary outcome(s))**

1. Smoking status measured using a CO monitor at baseline, 6 months and 12 months.
2. Dietary status measured using the Mediterranean diet score at baseline, 6 months and 12 months

3. Physical activity status measured using the RAPA score at baseline, 6 months and 12 months
4. Blood biochemicals (lipids, HbA1c) measured using the Roche COBAS analyser, at baseline, 6 months and 12 months
5. Resting physiological measurements measured using an Omron blood pressure monitor, measured two to three times by auscultation, and an average will be taken as the final measurement, and heart rate measured manually by radial pulse at baseline, 6 months and 12 months
6. Anthropometric measures (BMI, waist circumference) measured at baseline, 6 months and 12 months
7. Heart age score measured using the Heart Age calculator at baseline, 6 months and 12 months
8. Health literacy measured using the Health Literacy Score at baseline, 6 months and 12 months

**Completion date**

20/09/2022

## Eligibility

**Key inclusion criteria**

1. First-degree relatives of patients with premature CHD
2. Aged 30 years and older
3. Males and females
4. Maltese ethnicity
5. Seeking cardiovascular risk assessment
6. No history of cardiovascular disease

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Total final enrolment**

89

**Key exclusion criteria**

1. Participants must not have a history of rheumatoid arthritis and chronic kidney disease
2. Participants must not have contraindications against physical activities and are able to go up a flight of stairs comfortably
3. Participants must not be pregnant

**Date of first enrolment**

01/09/2020

**Date of final enrolment**

01/09/2021

## Locations

### Countries of recruitment

Malta

### Study participating centre

#### Mater Dei Hospital

Cardiac rehabilitation services

Msida

Malta

MSD 2090

## Sponsor information

### Organisation

University of Malta

### ROR

<https://ror.org/03a62bv60>

## Funder(s)

### Funder type

University/education

### Funder Name

University of Malta

## Results and Publications

### Individual participant data (IPD) sharing plan

Data is being handled, coded and stored in accordance with the Data Protection Act 2018, in line with GDPR EU 2016/679. Raw data will be stored in an encrypted personal computer and only the principal researcher (Justin L. Mifsud) and the supervisor (Joseph Galea) will have access to such data. When the data is analysed, it is planned to be published in a peer-reviewed journal and reported to reflect on all the predefined aims and objectives published in the study protocol.

(added 13/12/2021)

#### Availability of data and materials

The anonymised participant datasets generated and/or analysed during the current study will be made available in the University of Malta institutional open access data repository

<https://www.um.edu.mt/library/oar/>.

#### IPD sharing plan summary

Stored in publicly available repository

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Baseline findings	19/05/2025	05/09/2025	Yes	No
<a href="#">Protocol article</a>		09/08/2021	13/12/2021	Yes	No
<a href="#">Interim results article</a>		09/04/2024	25/04/2024	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet		28/09/2020	No	Yes
<a href="#">Participant information sheet</a>		11/11/2025	11/11/2025	No	Yes